



ASX Announcement

Dr Garner – Appendix 3Y

27 August 2020 – Race Oncology Limited (“Race” or “the Company”) (ASX: RAC) advises that on 8 February 2019, Update Pharma Inc (an entity controlled by Dr William Garner) undertook a divestment of its interest in Race Oncology Limited (ASX:RAC) (**Divestment**), as detailed in the Appendix 3Y dated 8 February 2019 (**Announcement**).

As part of the divestment, 107,696 fully paid ordinary shares in RAC (**Shares**) were transferred to Ms Ya Zou, Dr Garner’s spouse. However, as a result of an internal administration error, the 107,696 Shares were not attributed to Dr Garner in the Announcement. In order to remedy this error, RAC has released the following Appendix 3Y.

RAC has subsequently implemented additional internal procedures to ensure the oversight does not re-occur.

- ENDS -

About Race Oncology (RAC: ASX)

Race Oncology (RAC) is a drug development biotech with a Phase II/III cancer drug called bisantrene. RAC has compelling clinical data for Bisantrene in acute myeloid leukaemia (AML) as well as breast and ovarian cancer. RAC is pursuing an exciting ‘5-Path’ clinical development strategy that involves parallel US and Australian clinical trials in AML, breast and ovarian with clinical trials to begin in 2020.

Release authorised by:

Daniel Tillett, Chief Scientific Officer & Director

daniel.tillett@raceoncology.com

Media contact:

Jane Lowe, IR Department

+ 61 411 117 774

jane.lowe@irdepartment.com.au

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Race Oncology Limited
ABN	61 149 318 749

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	William James Garner
Date of last notice	11 March 2020

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	<ol style="list-style-type: none"> 1. Direct 2. Indirect 3. Indirect
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	<ol style="list-style-type: none"> 2. Citicorp Nominees Pty Ltd – Beneficial Interest 3. Ya Zou – Spouse of Dr Bill Garner
Date of change	8 February 2019
No. of securities held prior to change	<ol style="list-style-type: none"> 1. 13,705,078 Ordinary Shares 757,575 Options exercisable at \$0.099, expiring 31/08/2021 1,000,000 Options exercisable at \$0.25, expiring 25/11/2021 2. 225,000 Ordinary Shares
Class	Ordinary Shares
Number acquired	3. 107,696 Ordinary Shares
Number disposed	Nil
Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	Nil

Appendix 3Y

Change of Director's Interest Notice

No. of securities held after change	<ol style="list-style-type: none"> 13,705,078 Ordinary Shares 757,575 Options exercisable at \$0.099, expiring 31/08/2021 1,000,000 Options exercisable at \$0.25, expiring 25/11/2021 225,000 Ordinary Shares 107,696 Ordinary Shares
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	<ol style="list-style-type: none"> Off-market transfer by Update Pharma (Director Related Entity) to Ya Zou on 8 February 2019.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	Not applicable
Nature of interest	Not applicable
Name of registered holder (if issued securities)	Not applicable
Date of change	Not applicable
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	Not applicable
Interest acquired	Not applicable
Interest disposed	Not applicable
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	Not applicable
Interest after change	Not applicable

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	Not applicable
If prior written clearance was provided, on what date was this provided?	Not applicable

+ See chapter 19 for defined terms.